Keros Therapeutics Inc. (KROS)

The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.

Keros Therapeutics, Inc.‘s KROS board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale.

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday.

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, ...

The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago.

NEW YORK, NY / ACCESS Newswire / February 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors a...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint...

NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investo...